Published in PLoS One on November 18, 2013
Geographic Variations in Retention in Care among HIV-Infected Adults in the United States. PLoS One (2016) 0.81
Impact of Health Insurance, ADAP, and Income on HIV Viral Suppression Among US Women in the Women's Interagency HIV Study, 2006-2009. J Acquir Immune Defic Syndr (2016) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis (2011) 16.88
Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA (1999) 10.93
Vital signs: HIV prevention through care and treatment--United States. MMWR Morb Mortal Wkly Rep (2011) 6.90
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Improvement in the health of HIV-infected persons in care: reducing disparities. Clin Infect Dis (2012) 2.70
Optimizing resource allocation in United States AIDS drug assistance programs. Clin Infect Dis (2006) 2.45
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis (2011) 2.34
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Results of the Expanded HIV Testing Initiative--25 jurisdictions, United States, 2007-2010. MMWR Morb Mortal Wkly Rep (2011) 2.15
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Interval and clinical cohort studies: epidemiological issues. AIDS Res Hum Retroviruses (2007) 1.61
Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS (2013) 1.49
Clinical and behavioral characteristics of adults receiving medical care for HIV infection --- Medical Monitoring Project, United States, 2007. MMWR Surveill Summ (2011) 1.42
Inpatient health services utilization among HIV-infected adult patients in care 2002-2007. J Acquir Immune Defic Syndr (2010) 1.39
Recent trends in HIV-related inpatient admissions 1996-2000: a 7-state study. J Acquir Immune Defic Syndr (2003) 1.31
Disparities among US states in HIV-related mortality in persons with HIV infection, 2001-2007. AIDS (2012) 1.27
Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment. AIDS (2011) 1.19
What does U.S. health reform mean for HIV clinical care? J Acquir Immune Defic Syndr (2012) 1.15
HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. AIDS Care (2009) 1.14
Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS One (2011) 1.10
Current challenges to the United states' AIDS drug assistance program and possible implications of the affordable care act. AIDS Res Treat (2013) 1.08
Psychiatric correlates of HAART utilization and viral load among HIV-positive impoverished persons. AIDS (2011) 1.05
A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care. J Acquir Immune Defic Syndr (2011) 1.01
The impact of the AIDS Drug Assistance Program (ADAP) on use of highly active antiretroviral and antihypertensive therapy among HIV-infected women. J Acquir Immune Defic Syndr (2011) 0.98
AIDS Drug Assistance Programs: highlighting inequities in human immunodeficiency virus-infection health care in the United States. Clin Infect Dis (2002) 0.98
State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards. Med Care (2002) 0.96
Improving outcomes in state AIDS drug assistance programs. J Acquir Immune Defic Syndr (2009) 0.96
HIV/AIDS: AIDS Drug Assistance Programs in the era of routine HIV testing. Clin Infect Dis (2008) 0.95
AIDS Drug Assistance Programs: managers confront uncertainty and need to adapt as the Affordable Care Act kicks in. Health Aff (Millwood) (2013) 0.92
State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors. J Gen Intern Med (2011) 0.90
Location, race, and hospital care for AIDS patients: an analysis of 10 states. Inquiry (2001) 0.90
Underutilization of the AIDS Drug Assistance Program: associated factors and policy implications. Health Serv Res (2011) 0.85
Is the US AIDS drug assistance program cost-effective? AIDS Behav (2013) 0.84
HIV-1 RNA and viral load. Clin Lab Med (2002) 0.83
The adoption of mental health drugs on state AIDS drug assistance program formularies. Am J Public Health (2011) 0.79
Sticky Dollars: Inertia in the Evolution of Federal Allocations for HIV Care through the Ryan White HIV/AIDS Program. Publius (2011) 0.77
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med (2010) 11.99
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis (2003) 8.00
Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood (2004) 7.09
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
Tuberculosis. Lancet (2003) 6.39
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis (2009) 6.17
Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis (2008) 6.03
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA (2008) 5.68
Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet (2006) 5.34
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS (2008) 5.30
Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst (2005) 5.29
An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med (2006) 5.02
Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis (2009) 4.96
Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation (2004) 4.87
Competing risk regression models for epidemiologic data. Am J Epidemiol (2009) 4.75
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS (2004) 4.64
Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis (2005) 4.27
Improving propensity score weighting using machine learning. Stat Med (2010) 4.22
Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr (2010) 4.20
Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. AIDS (2004) 4.17
Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis (2007) 4.10
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS (2007) 4.09
Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med (2010) 4.07
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science (2004) 3.95
Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr (2005) 3.92
Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis (2009) 3.91
De facto long-term opioid therapy for noncancer pain. Clin J Pain (2008) 3.85
Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep (2010) 3.80
The therapeutic implications of timely linkage and early retention in HIV care. AIDS Patient Care STDS (2009) 3.78
The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr (2007) 3.76
A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr (2009) 3.76
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS (2008) 3.66
Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis (2003) 3.63
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS (2002) 3.45
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis (2011) 3.38
Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis (2007) 3.36
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV? J Gen Intern Med (2006) 3.25
Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf (2009) 3.25
Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med (2014) 3.24
Intervention targeting development of socially synchronous engagement in toddlers with autism spectrum disorder: a randomized controlled trial. J Child Psychol Psychiatry (2010) 3.20
Sampling-based approaches to improve estimation of mortality among patient dropouts: experience from a large PEPFAR-funded program in Western Kenya. PLoS One (2008) 3.19
Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care (2005) 3.19
Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis (2008) 3.17
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15